{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:47:16Z","timestamp":1769312836256,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.prro.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T20:04:00Z","timestamp":1737576240000},"page":"120-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lorlatinib-Induced Blindness: A Rare Entity"],"prefix":"10.1016","volume":"15","author":[{"given":"Neris","family":"Dincer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orcun","family":"Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enis","family":"Ozyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.01.004_bib0001","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.01.004_bib0002","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.prro.2025.01.004_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1188\/16.ONF.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis","year":"2016","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.prro.2025.01.004_bib0004","first-page":"415","article-title":"Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy","volume":"22","author":"Grodzka","year":"2023","journal-title":"Excli J"},{"key":"10.1016\/j.prro.2025.01.004_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14737140.2020.1744438","article-title":"Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer","volume":"20","author":"Choo","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.prro.2025.01.004_bib0006","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.01.004_bib0007","unstructured":"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer, version 9, 2024. Accessed September 16, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.prro.2025.01.004_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prro.2025.01.004_bib0009","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.01.004_bib0010","article-title":"Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma","volume":"34","author":"Kong","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.prro.2025.01.004_bib0011","doi-asserted-by":"crossref","first-page":"50","DOI":"10.37047\/jos.2022-92714","article-title":"Lorlatinib-related vision loss: Two cases of non-small cell lung cancer with blindness","volume":"9","author":"Karakaya","year":"2023","journal-title":"J Oncol Sci"},{"key":"10.1016\/j.prro.2025.01.004_bib0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2018.01.053","article-title":"Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.01.004_bib0013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/01658107.2020.1817946","article-title":"Radiation-induced optic neuropathy: Literature review","volume":"45","author":"Ata\u00eddes","year":"2021","journal-title":"Neuro-Ophthalmology"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:14:28Z","timestamp":1754723668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1879850025000062"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.01.004","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorlatinib-Induced Blindness: A Rare Entity","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}